EA201100464A1 - Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение - Google Patents
Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применениеInfo
- Publication number
- EA201100464A1 EA201100464A1 EA201100464A EA201100464A EA201100464A1 EA 201100464 A1 EA201100464 A1 EA 201100464A1 EA 201100464 A EA201100464 A EA 201100464A EA 201100464 A EA201100464 A EA 201100464A EA 201100464 A1 EA201100464 A1 EA 201100464A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- pharmaceutical composition
- application
- hyperproliferative diseases
- biotechnology
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к области биотехнологии и медицины, в частности к фармацевтической композиции, обладающей антипролиферативной активностью и способу лечения онкологических заболеваний, включающему введение указанного химерного пептида нуждающемуся в таком лечении млекопитающему. Задачей изобретения является разработка препарата, эффективно проникающего в клетки-мишени и обладающего высоким цитостатическим и цитотоксическим действием.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201100464A EA017179B1 (ru) | 2011-04-06 | 2011-04-06 | Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение |
US14/002,860 US8969515B2 (en) | 2011-04-06 | 2011-05-20 | Pharmaceutical composition for treating hyperproliferative diseases |
JP2014503623A JP5852731B2 (ja) | 2011-04-06 | 2011-05-20 | 高増殖性疾患治療のための医薬組成物 |
EP11863085.4A EP2712621B1 (en) | 2011-04-06 | 2011-05-20 | Pharmaceutical composition for treating hyperproliferative diseases |
PCT/RU2011/000343 WO2012138246A1 (ru) | 2011-04-06 | 2011-05-20 | Фармацевтическая композиция для лечения гиперпролиферативных заболеваний |
US14/599,426 US20150174191A1 (en) | 2011-04-06 | 2015-01-16 | Pharmaceutical composition for treating hyperproliferative diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201100464A EA017179B1 (ru) | 2011-04-06 | 2011-04-06 | Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201100464A1 true EA201100464A1 (ru) | 2012-10-30 |
EA017179B1 EA017179B1 (ru) | 2012-10-30 |
Family
ID=46969422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201100464A EA017179B1 (ru) | 2011-04-06 | 2011-04-06 | Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение |
Country Status (5)
Country | Link |
---|---|
US (2) | US8969515B2 (ru) |
EP (1) | EP2712621B1 (ru) |
JP (1) | JP5852731B2 (ru) |
EA (1) | EA017179B1 (ru) |
WO (1) | WO2012138246A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA028151B1 (ru) * | 2013-04-03 | 2017-10-31 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "МетаМакс" (ООО "МетаМакс") | Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9519275D0 (en) * | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
ES2237103T3 (es) * | 1998-05-15 | 2005-07-16 | Aphton Corporation | Terapia de combinacion para el tratamiento de tumores. |
WO2002050102A2 (en) * | 2000-12-20 | 2002-06-27 | Novartis Ag | Inhibitors of the e2f-1/cyclin interaction for cancer therapy |
RU2297241C2 (ru) * | 2004-11-22 | 2007-04-20 | Государственное учреждение Российский научный центр рентгенорадиологии Министерства здравоохранения и социального развития | Химерный белок для лечения злокачественных лимфом |
US8173604B2 (en) * | 2006-05-24 | 2012-05-08 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibition of Skp2-cyclin a interaction |
CN101801401A (zh) * | 2007-03-16 | 2010-08-11 | 佛罗里达大学研究基金会 | 激酶蛋白质结合抑制剂 |
AU2008272818A1 (en) * | 2007-07-02 | 2009-01-08 | Yu, Ming Dr | Methods, composition, targets for combinational cancer treatments |
RU2369402C1 (ru) * | 2008-04-17 | 2009-10-10 | Федеральное Государственное Учреждение "Российский научный центр рентгенорадиологии Федерального агентства по высокотехнологичной медицинской помощи" | Химерный пептид для лечения эпителиальных и мезенхимальных злокачественных новообразований |
-
2011
- 2011-04-06 EA EA201100464A patent/EA017179B1/ru unknown
- 2011-05-20 US US14/002,860 patent/US8969515B2/en not_active Expired - Fee Related
- 2011-05-20 EP EP11863085.4A patent/EP2712621B1/en active Active
- 2011-05-20 JP JP2014503623A patent/JP5852731B2/ja active Active
- 2011-05-20 WO PCT/RU2011/000343 patent/WO2012138246A1/ru active Application Filing
-
2015
- 2015-01-16 US US14/599,426 patent/US20150174191A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2712621A4 (en) | 2014-10-29 |
US20150174191A1 (en) | 2015-06-25 |
EP2712621A1 (en) | 2014-04-02 |
WO2012138246A1 (ru) | 2012-10-11 |
EP2712621B1 (en) | 2018-08-08 |
US8969515B2 (en) | 2015-03-03 |
JP2014510135A (ja) | 2014-04-24 |
EA017179B1 (ru) | 2012-10-30 |
US20140051644A1 (en) | 2014-02-20 |
JP5852731B2 (ja) | 2016-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501790B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
PH12016501788A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
EA201500207A1 (ru) | Гетероароматические соединения в качестве ингибиторов втк | |
EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
EA201500132A1 (ru) | Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний | |
MX353608B (es) | Anticuerpo modificado en el que el tema que comprende residuos de cisteina esta ligado, conjugado de farmaco de anticuerpo modificado que comprende el anticuerpo modificado y metodo de produccion para el mismo. | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
IN2015DN00376A (ru) | ||
TW201129382A (en) | Antibody formulation and therapeutic regimens | |
UA111579C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ | |
IN2014MN00986A (ru) | ||
CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
EA201171285A1 (ru) | Новая технология изготовления диклофенака | |
EA201300137A1 (ru) | Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями | |
IN2015DN00450A (ru) | ||
MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
BR112017025698A2 (pt) | composições e métodos para inibir a expressão do gene de hif2alfa | |
EA201491500A1 (ru) | Способы лечения фиброза | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
EA201792256A1 (ru) | Соли и пролекарства 1-метил-d-триптофана | |
BR112016023011A2 (pt) | tratamento de câncer gástrico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC4A | Registration of transfer of a eurasian patent by assignment |